Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
University of Florida
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
University of Leipzig
Washington University School of Medicine
Rush University Medical Center
Rush University Medical Center
Jonsson Comprehensive Cancer Center
Brown University
University of Florida
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
AIDS Malignancy Consortium
SWOG Cancer Research Network
Eleos, Inc.
University of Cincinnati